raloxifene has apparently not done well in the draft NICE report either...
Lesley
-----Original Message-----
From: GP-UK [mailto:[log in to unmask]]On Behalf Of Paul Caldwell
Sent: 17 February 2004 10:32
To: [log in to unmask]
Subject: Wot now for HRT?
V occasionally a BMJ editorial changes my clinical practice. This weeks one
on HRT will do so. Wot now for HRT? It seems relegated to short-term
treatment of incapacitating menopausal symps in those women willing to take
the risk of an MI/PE in the first year of treatment. + wot about
osteoporosis prevention? Now must it be raloxifene or bisphosphonate? and
have these been subject to longterm follow-up? and r they as good as HRT
(not seems to be the conscensus)? Most women who get osteoporosis by age 65
r not in the known risk groups either. Anyone still got shares in HRT drug
companies or bought shares in alendronate?! I'm confused let alone the pts..
10 years ago HRT clinicians were arguing, rightly, that the post-menopause
state was unnatural (cats, dogs or chimps who go thru it die quickly) and
that HRT was manna from heaven.
_________________________________________________________________
Watch high-quality video with fast playback at MSN Video. Free!
http://click.atdmt.com/AVE/go/onm00200365ave/direct/01/
|